跳至主要内容
临床试验/NCT04751175
NCT04751175招募中4 期

Ketamine and Dexametasone in the Management of Pain in Lumbar Arthrodesis

Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta1 个研究点 分布在 1 个国家目标入组 128 人开始时间: 2013年7月4日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
128
试验地点
1
主要终点
Efficacy of Morphic Chloride (PCA) to treat pain during the post-operative period. Consumption of morphics will be evaluated

研究概览

简要总结

KETAMINE AND DEXAMETASONE IN THE MANAGEMENT OF PAIN IN LUMBAR ARTHRODESISPhase IV prospective randomized controlled single-center clinical trial to determine the effect of intravenous ketamine and dexamethasone administration perioperatively in patients undergoing lumbar arthrodesis.

详细描述

The need to carry out this study is to evaluate the analgesic effects after the administration of ketamine and dexamethasone intravenously perioperatively in patients undergoing lumbar arthrodesis and, likewise, study the incidence of pain and protocolize perioperative analgesia.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

盲法说明

To preserve the masking of the study, the randomization system has been carried out by the pharmacy service personnel using the EPIDAT 4.0 program and only the personnel responsible for the pharmacy will know the randomization tables and codes. The main investigator will have the emergency codes in case of need by contacting the pharmacy service

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female
  • Age> 18 years
  • ASA I-III.
  • Lumbar arthrodesis.
  • Patients who have signed the preoperative informed consent for participation in the study.

排除标准

  • Unstable coronary heart disease
  • History of allergy to ketamine, dexamethasone, or morphic chloride
  • Dementia or inability to understand IC and study
  • Pluricomplicated diabetes mellitus difficult to control
  • Patients who have taken an experimental drug 30 days before the start of the study or who are included in any type of study of an experimental drug

研究组 & 干预措施

Ketamina bolus plus Dexamethasone bolus plus infusion ketamine

Experimental

Ketamine bolus (0.5 mg / kg) + dexamethasone 0.1 mg / kg bolus + ketamine infusion (0.1 mg / kg / h) up to three hours after admission to the Post-Anesthesia Resuscitation Unit (URPA)

干预措施: Ketamine (Drug)

Ketamina bolus plus Dexamethasone bolus plus infusion ketamine

Experimental

Ketamine bolus (0.5 mg / kg) + dexamethasone 0.1 mg / kg bolus + ketamine infusion (0.1 mg / kg / h) up to three hours after admission to the Post-Anesthesia Resuscitation Unit (URPA)

干预措施: Dexamethasone (Drug)

Ketamine bolus plus ketamine infusion

Experimental

Ketamine bolus (0.5 mg / kg) + physiological serum bolus + ketamine infusion (0.1 mg / kg / h) up to three hours after admission to the URPA.

干预措施: Ketamine (Drug)

Ketamine bolus plus ketamine infusion

Experimental

Ketamine bolus (0.5 mg / kg) + physiological serum bolus + ketamine infusion (0.1 mg / kg / h) up to three hours after admission to the URPA.

干预措施: Physiologic saline (Drug)

Dexametasone arm

Active Comparator

Saline bolus + dexamethasone bolus 0.1 mg / kg + saline infusion up to three hours after admission in URPA

干预措施: Dexamethasone (Drug)

Dexametasone arm

Active Comparator

Saline bolus + dexamethasone bolus 0.1 mg / kg + saline infusion up to three hours after admission in URPA

干预措施: Physiologic saline (Drug)

Saline bolus

Placebo Comparator

Saline bolus + saline bolus + saline infusion up to three hours after admission to the URPA

干预措施: Physiologic saline (Drug)

结局指标

主要结局

Efficacy of Morphic Chloride (PCA) to treat pain during the post-operative period. Consumption of morphics will be evaluated

时间窗: 4 hours post operative

Consumption of morphics

次要结局

  • Incidence of postoperative nausea and vomiting (PONV).(4 hours post operative)
  • Efficay of study treatment regarding pain at 3 postoperative months(3 months)
  • Adverse side effects:Hallucinations / Delirium.Sedation. Diplopia, Hyperglycemia Respiratory depression (Sat <90%)(4 hours post operative)

研究者

发起方
Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr Emili Leon

Principal Investigator

Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta

研究点 (1)

Loading locations...

相似试验